Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC) Meeting Abstract
| Authors: | Kelley, R. K.; Sangro, B.; Harris, W. P.; Ikeda, M.; Okusaka, T.; Kang, Y. K.; Qin, S.; Tai, W. M. D.; Lim, H. Y.; Yau, T.; Yong, W. P.; Cheng, A. L.; Gasbarrini, A.; De Braud, F. G.; Bruix, J.; Borad, M. J.; He, P.; Negro, A.; Kudo, M.; Abou-Alfa, G. K. |
| Abstract Title: | Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 237s |
| Language: | English |
| ACCESSION: | WOS:000560368302129 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.4508 |
| Notes: | Meeting Abstract: 4508 -- Source: Wos |
